Halozyme Wins Injunction Against Merck in Keytruda Patent Case -- Update
Dow Jones2026/10/07 15:31By Connor Hart Halozyme Therapeutics was granted a court order that will prevent Merck from manufacturing and distributing a formulation of its blockbuster cancer treatment in several European markets. The specialized Dutch patent court of the Hague found Merck to be infringing upon one of Halozyme's patents, ordering Merck to refrain from manufacturing and selling Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, Halozyme said Wednesday. The ruling came after Halozyme last year was granted a preliminary injunction that stopped the launch of Keytruda SC in Germany. Halozyme has additionally sued Merck for patent infringement in New Jersey federal courts. Merck said it strongly disagrees with the ruling. "We consider Halozyme's patent to be invalid globally and its allegation of infringement to be without merit," a company spokesperson said. "We are evaluating next steps but are confident in our overall legal position and believe that, ultimately, we will prevail in the courts." Halozyme noted that patients who want to use Keytruda will still have access to the IV version of the drug, which is not covered by Halozyme's patent or the court's injunction order. Write to Connor Hart at [email protected] (END) Dow Jones Newswires October 07, 2026 11:31 ET (15:31 GMT)
By Connor Hart
Halozyme Therapeutics was granted a court order that will prevent Merck from manufacturing and distributing a formulation of its blockbuster cancer treatment in several European markets.
The specialized Dutch patent court of the Hague found Merck to be infringing upon one of Halozyme's patents, ordering Merck to refrain from manufacturing and selling Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, Halozyme said Wednesday.
The ruling came after Halozyme last year was granted a preliminary injunction that stopped the launch of Keytruda SC in Germany. Halozyme has additionally sued Merck for patent infringement in New Jersey federal courts.
Merck said it strongly disagrees with the ruling.
"We consider Halozyme's patent to be invalid globally and its allegation of infringement to be without merit," a company spokesperson said. "We are evaluating next steps but are confident in our overall legal position and believe that, ultimately, we will prevail in the courts."
Halozyme noted that patients who want to use Keytruda will still have access to the IV version of the drug, which is not covered by Halozyme's patent or the court's injunction order.
Write to Connor Hart at [email protected]
(END) Dow Jones Newswires
October 07, 2026 11:31 ET (15:31 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pyth October Report: ARR Jumps 18.9% as Data Expansion Accelerates
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Crypto prices
More
